Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Cinnarizine is the active ingredient of these drugs:
Hong Kong
Hong Kong
Hong Kong Singapore
Hong Kong
Hong Kong
Cyprus Singapore
Hong Kong
Brazil
Hong Kong
Brazil Cyprus Ireland Lithuania Singapore
Hong Kong
Hong Kong
Cinnarizine is also found within below combination drugs:
ARLEVERT , AZALONUM , CINNAGO , CLINADIL , PHEZAM , PRIMATOUR , TRAVELLER
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):